EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION
Purpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov regional clinical oncology dispensary.Materials and...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
“ABV-press” Publishing house”, LLC
2015-02-01
|
| Series: | Тазовая хирургия и онкология |
| Subjects: | |
| Online Access: | https://ok.abvpress.ru/jour/article/view/86 |
| _version_ | 1797757058421882880 |
|---|---|
| author | N. Z. Sherman M. S. Ramazanova Ye. N. Gopachenko |
| author_facet | N. Z. Sherman M. S. Ramazanova Ye. N. Gopachenko |
| author_sort | N. Z. Sherman |
| collection | DOAJ |
| description | Purpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov regional clinical oncology dispensary.Materials and methods. The study was conducted in Kirov regional clinical oncology dispensary from 2008 until 2014. 35 patients treated with combined first line therapy including bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab were retrospectively evaluated. Overall response was evaluated using RECIST ver. 1.1 criteria. Long term outcomes – progression free and overall survival were evaluated. Treatment safety was evaluated using NCI CTCAE.Results. There were no complete remissions in second line bevacizumab treatment, partial remissions were detected for 4 (22.2 %) patients, stable disease for 14 (77.8 %). Median progression free survival in both groups was comparable 9.1 and 10.4 months respectively. Patients treated with bevacizumab in first and second lines of treatment had 8.2 months survival benefit (p > 0.05).Conclusions. Combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with bevacizumab improves overall survival on 8.2 months in comparison with patients who stopped bevacizumab treatment after first disease progression. |
| first_indexed | 2024-03-12T18:10:32Z |
| format | Article |
| id | doaj.art-a72cd3a78a3741ba82ac36fb39d1c473 |
| institution | Directory Open Access Journal |
| issn | 2686-9594 |
| language | Russian |
| last_indexed | 2024-03-12T18:10:32Z |
| publishDate | 2015-02-01 |
| publisher | “ABV-press” Publishing house”, LLC |
| record_format | Article |
| series | Тазовая хирургия и онкология |
| spelling | doaj.art-a72cd3a78a3741ba82ac36fb39d1c4732023-08-02T09:16:27Zrus“ABV-press” Publishing house”, LLCТазовая хирургия и онкология2686-95942015-02-0104273110.17650/2220-3478-2014-0-4-27-3180EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGIONN. Z. Sherman0M. S. Ramazanova1Ye. N. Gopachenko2Department of Chemotherapy, Kirov Regional Clinical Oncology DispensaryDepartment of Oncology, Kirov State Medical Academy, Ministry of Health of RussiaDepartment of Chemotherapy, Kirov Regional Clinical Oncology DispensaryPurpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov regional clinical oncology dispensary.Materials and methods. The study was conducted in Kirov regional clinical oncology dispensary from 2008 until 2014. 35 patients treated with combined first line therapy including bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab were retrospectively evaluated. Overall response was evaluated using RECIST ver. 1.1 criteria. Long term outcomes – progression free and overall survival were evaluated. Treatment safety was evaluated using NCI CTCAE.Results. There were no complete remissions in second line bevacizumab treatment, partial remissions were detected for 4 (22.2 %) patients, stable disease for 14 (77.8 %). Median progression free survival in both groups was comparable 9.1 and 10.4 months respectively. Patients treated with bevacizumab in first and second lines of treatment had 8.2 months survival benefit (p > 0.05).Conclusions. Combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with bevacizumab improves overall survival on 8.2 months in comparison with patients who stopped bevacizumab treatment after first disease progression.https://ok.abvpress.ru/jour/article/view/86metastatic colorectal cancerbevacizumabfirst-line treatmentmaintenance therapysecond-line treatment |
| spellingShingle | N. Z. Sherman M. S. Ramazanova Ye. N. Gopachenko EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION Тазовая хирургия и онкология metastatic colorectal cancer bevacizumab first-line treatment maintenance therapy second-line treatment |
| title | EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION |
| title_full | EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION |
| title_fullStr | EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION |
| title_full_unstemmed | EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION |
| title_short | EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION |
| title_sort | experience of bevacizumab use in patients with inoperable colorectal cancer in kirov region |
| topic | metastatic colorectal cancer bevacizumab first-line treatment maintenance therapy second-line treatment |
| url | https://ok.abvpress.ru/jour/article/view/86 |
| work_keys_str_mv | AT nzsherman experienceofbevacizumabuseinpatientswithinoperablecolorectalcancerinkirovregion AT msramazanova experienceofbevacizumabuseinpatientswithinoperablecolorectalcancerinkirovregion AT yengopachenko experienceofbevacizumabuseinpatientswithinoperablecolorectalcancerinkirovregion |